Cargando…
Efmoroctocog Alfa: A Review in Haemophilia A
Efmoroctocog alfa (Elocta(®), Eloctate(®), Eloctate™), an extended half-life (EHL) recombinant factor VIII (rFVIII)-Fc fusion protein, is approved for the treatment and prophylaxis of bleeding in patients with haemophilia A. The efficacy of efmoroctocog alfa in the prevention and treatment of bleedi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636404/ https://www.ncbi.nlm.nih.gov/pubmed/34743314 http://dx.doi.org/10.1007/s40265-021-01615-w |